


Study in a real-world setting in Argentina

# EFFICACY OF AN EHF WITH SYNPBiotics IN INFANTS WITH CMA



Soria, et al. Front. Allergy. 2023;4:1265083.


## Patient Group

- 65 infants with suspected or confirmed CMA
- Argentina multicenter
- Recruited at the point of first hypoallergenic formula prescription

## Method

- Single arm observational, prospective study
- 28 days intervention period; EHF with synbiotics (exclusively formula-fed or mixed-fed)
- Synbiotic blend: *Bifidobacterium breve M-16V* (probiotic) and short chain galacto- and long chain fructo- oligosaccharides (prebiotic)

## Results

**EHF with synbiotics demonstrated CMA symptom resolution or improvement**


### Gastrointestinal symptoms

**92%**

of infants' GI symptoms were resolved or improved

- Reduced** frequency of stools and parent reported improvement of stool consistency
- Reduced** frequency of regurgitations and parent reported discomfort due to regurgitation



### Skin symptoms

**87.5%**

of infants' skin symptoms were resolved or improved



### Significant improvement in quality of life

- Reduced** crying time and improvement of sleeping patterns
- Reduced** the family burden associated with CMA

### AN EHF WITH SYNPBiotics IS:

- Well tolerated**
- Well accepted**
- Supports normal growth**

## Conclusions

In this study, in a real-world setting, the use of an EHF with synbiotics demonstrated **improvement of overall, gastrointestinal, and dermatological allergy symptoms**.

Data demonstrated a **significant reduction in the frequency of regurgitation and bowel movements, and an improvement in stool consistency**.

Parents also reported an **improvement in sleep patterns and quality of life**.